Dacryocystitis Treatment Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Dacryocystitis Treatment Market covers analysis By Product (Oral Antibiotics, Systemic Antibiotics, Surgery, Other); Application (Acute Dacryocystitis, Chronic Dacryocystitis, Congenital Dacryocystitis, Other); End-user (Hospitals, Ambulatory Surgical Centers, Eye Care Centers, Retail Pharmacies, Drug Stores, Others.) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00023211
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET OVERVIEW



Dacryocystitis refers to an inflammation of the lacrimal gland (tear sac). It is caused due to obstruction within the nasolacrimal duct and subsequent stagnation in the lacrimal sac. These infections may be acute or chronic. Its symptom includes pain, redness, and swelling over the inner aspect of the lower eyelid and epiphora. These infections generally occur in infants and adults over the age of 40. The treatment choice depends on the indication of dacryocystitis, such as oral antibiotics, systemic antibiotics (in most complicated cases), and surgery for recurring infections.

MARKET SCOPE



The

"Global Dacryocystitis Treatment Market Analysis to 2031"

is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the dacryocystitis treatment market with detailed market segmentation by product, application, end-user, and geography. The report provides key statistics on the market status of the leading dacryocystitis treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



  •  Based on product, the global dacryocystitis treatment market is segmented into oral antibiotics, systemic antibiotics, surgery and other.
  •  On the basis of application, the market is segmented into acute dacryocystitis, chronic dacryocystitis, congenital dacryocystitis and other.
  •  On the basis of end-users, the market is bifurcated into hospitals, ambulatory surgical centers, eye care centers, retail pharmacies, drug stores and others.

MARKET DYNAMICS


Drivers



  •   The increasing prevalence of eye infections and technological advancements drive the dacryocystitis treatment market.
  •   Growing clinical research and subsequent new product launches boosts the market growth.
  •   Scientific advancements in the developed economies fuel market growth.
  •   The rising surgical procedures associated with nasal and eye infections propel the market growth.

Restraints



  •   Low healthcare expenditure in developing economies
  •   Lack of patient awareness regarding various treatment procedures.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The dacryocystitis treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the dacryocystitis treatment market in these regions.

IMPACT OF COVID-19 ON DACRYOCYSTITIS TREATMENT MARKET



COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The market experienced fluctuations due to worldwide lockdown, business shutdown, and trade restrictions. The cancellation of all non-urgent and elective surgical procedures led to a decreased patient pool. Moreover, to slow the virus transmission, people gathering at clinics and hospitals were avoided. However, as all infected patients were not able to get treatment hence, the market may experience slow growth in the future after the removal of restrictive measures.

MARKET PLAYERS



The report covers key developments in the dacryocystitis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from dacryocystitis treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for dacryocystitis treatment in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the dacryocystitis treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Pfizer
  •  Abbott Laboratories
  •  Glaxosmithkline
  •  Mylan
  •  Cipla
  •  FCI Ophthalmics
  •  Aurolab
  •  Kaneka
  •  Gunther Weiss Scientific Glass
  •  Bess Medizintechnik GmbH

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Dacryocystitis Treatment Report Scope

Report Attribute Details
Market size in 2023 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) XX%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Oral Antibiotics
  • Systemic Antibiotics
  • Surgery
By Application
  • Acute Dacryocystitis
  • Chronic Dacryocystitis
  • Congenital Dacryocystitis
By End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Eye Care Centers
  • Retail Pharmacies
  • Drug Stores
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Pfizer
  • Abbott Laboratories
  • Glaxosmithkline
  • Mylan
  • Cipla
  • FCI Ophthalmics
  • Aurolab
  • Kaneka
  • Gunther Weiss Scientific Glass
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. Pfizer
    2. Abbott Laboratories
    3. Glaxosmithkline
    4. Mylan
    5. Cipla
    6. FCI Ophthalmics
    7. Aurolab
    8. Kaneka
    9. Gunther Weiss Scientific Glass
    10. Bess Medizintechnik GmbH

    Buy Now